AMIX Company Profile and Key Details

Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $5.00 to $5.00. The high target offers -6.89% upside. The low target suggests -6.89% downside. The mean target is $5.00. This offers -6.89% upside. Autonomix Medical, Inc. earnings surprise history is a mixed track record. The quarter that ended August 12, 2026, missed forecasts by -21.62%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in November 12, 2025.

AMIX has shown weak momentum, losing -7.9% over the past week and -58.83% over the past quarter, though year-to-date performance is down -15.42%. Short-term trend indicators are bullishly aligned (SMA20 5.92%, SMA50 -13.63%, SMA200 -60.73%). The stock’s 14-day RSI is 47.41 (neutral), while the ATR of 0.04 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -86.34% below its high and over 20.03% above its low. Average 10-day trading volume of 2.36 million shares is below the 3-month average of 3.98 million, indicating normal recent market interest.

Autonomix Medical, Inc. has 971.04 thousand shares outstanding. The public float is 954.18 thousand shares, elevated short interest at 50.11% of float. This equals 263.44 thousand shares. The short ratio is 0.06 days. Institutional investors hold 4.4% of the float. Insiders own 4.11%.

Autonomix Medical, Inc. (NASDAQ:AMIX) closed at $5.37 USD, gaining $0.10 (1.90%) from the previous close of $5.27. The stock is currently mid-range between its 52-week high and low $2.44 and $32.55. With a market capitalization of about $2.92 million, Autonomix Medical, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-1.30). Key stats such as the average daily volume over the past year has been around 3.97 million shares, trading with heavier-than-usual volume. Headquartered in The Woodlands, TX, Autonomix Medical, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Bradley A. Hauser, the company employs approximately 10 people and listed since January 29, 2024. Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system.

Autonomix Medical, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $20.38. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that Autonomix Medical, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 15.46%, with price expected at $6.20 by September 07, 2026, within a range of $2.02 to $9.87 3-Month Outlook: Projected rise of 14.15%, reaching $6.13 by November 20, 2026, with a range of $5.25 to $7.18. 1-Year Outlook: Projected loss of -93.48%, with price at $0.35 by August 24, 2027, within a range of $0.00 to $11.03.

Autonomix Medical, Inc. (NASDAQ:AMIX) shares are down -15.42% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Autonomix Medical, Inc. trading at a premium to the broader market with a P/E of -0.11. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $5.00, suggesting -6.89% downside. Our AI forecast model points to short-term strength (15.46% over two weeks), a medium-term rise (14.15% over three months), and a longer-term loss (-93.48% over one year), with expected trading ranges indicating moderate volatility.

Autonomix Medical, Inc. trades at a P/E ratio of -0.11, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.88 suggesting the stock is closer to book value. The P/FCF stands at -0.23, also above market averages.